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Tissue-specific gene silencing monitored in circulating RNA
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ABSTRACT
Pharmacologic target gene modulation is the primary objective for RNA antagonist strategies and gene therapy. Herewe show that
mRNAs encoding tissue-specific gene transcripts can be detected in biological fluids and that RNAi-mediated target gene silencing
in the liver and brain results in quantitative reductions in serum and cerebrospinal fluid mRNA levels, respectively. Further,
administration of an anti-miRNA oligonucleotide resulted in decreased levels of the miRNA in circulation. Moreover, ectopic
expression of an adenoviral transgene in the liver was quantified based on measurement of serum mRNA levels. This
noninvasive method for monitoring tissue-specific RNA modulation could greatly advance the clinical development of RNA-
based therapeutics.
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INTRODUCTION
Previously, it has been shown thatmessenger RNAs andmicro
RNAs derived from various tissues can be detected in circula-
tion (Kamm and Smith 1972; Hunter et al. 2008). The circu-
lating RNA is associated with vesicular structures, such as
exosomes, and other ribonucleoprotein particles and is there-
by protected fromnucleolytic degradation (Smalheiser 2007).
While the function of circulating RNA remains incompletely
described, it has been suggested that it plays a role in intercel-
lular signaling innormal anddiseased states (Smalheiser 2007;
Valadi et al. 2007; Hood et al. 2011; Record et al. 2011). In ad-
dition, it has beenproposed that circulatingRNAcanbeuseful
in diagnostic applications in different disease settings (Chan
et al. 2003; O’Driscoll 2007; Conde-Vancells et al. 2008;
Raimondo et al. 2011). However, the quantification of circu-
latingmRNAandmicro-RNA(miRNA) as amethod formon-
itoring tissue-specific RNA modulation remains to be
described.
Here we demonstrate that RNAi-mediated target gene si-
lencing in the liver by systemic administration of siRNA re-
sults in quantitative reductions in serum mRNA levels that
closely corroborate with the degree and kinetics of tissue
mRNA silencing, including proof of the RNAi mechanism
of action. Further, administration of an anti-miRNA oligo-
nucleotide directed against a liver-specific miRNA was found
to result in decreased levels of the miRNA in circulation.
Another application of this technique was demonstrated by
quantification of liver expression of an adenoviral transgene
using circulating mRNA. Finally, this technique was extended
to a different tissue, where silencing of a brain-expressed
mRNA was monitored and quantified in cerebrospinal fluid
(CSF) following intraparenchymal CNS infusion of a specific
siRNA.
RESULTS AND DISCUSSION
To confirm that liver-specific mRNAs can be detected in se-
rum, filtered rat serum was subjected to high-speed centrifu-
gation, and total RNA was isolated from the resulting pellet.
To maximize recovery of RNA, LiCl was added to a final con-
centration of 1 M prior to centrifugation. As shown in Figure
1A, mRNAs corresponding to the liver-expressed genes Ttr,
Serpina1, Alb, and FVII could be detected by reverse-tran-
scription quantitative PCR (RT-qPCR). In addition, mRNA
derived from the ubiquitously expressed gene Gapdh was de-
tected. Similarly, TTR, SERPINA1, and GAPDH mRNA
could be detected in RNA isolated from cynomolgus monkey
(Macaca fascicularis) and human serum processed in a com-
parable manner (Fig. 1B). Between fourfold and 15-fold
higher levels ofGapdh, Alb, Actb, and TtrmRNAwere detect-
ed in rat serum samples prepared with, versus without, LiCl
addition, indicating the importance of this step in the proce-
dure (Fig. 1C). We could also measure levels of liver- and tu-
mor-specific transcripts in serum obtained from patients4Corresponding author
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with liver tumors, suggesting that this method can be extend-
ed into diseased tissues (Fig. 1D). Both α-fetoprotein (AFP)
and glypican-3 (GPC3) are commonly expressed in hepato-
cellular carcinoma and serve as diagnostic serum protein
markers (Bertino et al. 2012). As expected, the mRNA for
AFP and GPC3 were not detected in normal human plasma
samples (data not shown).
Since liver-specific mRNAs were found in circulation, we
next asked whether siRNA-mediated gene silencing in liver
would result in corresponding reductions in serum mRNA
levels for the specific genes targeted. Accordingly, rats were
treated with a single intravenous dose of 0.3 mg/kg lipid
nanoparticle (LNP) formulated siRNA targeting Ttr, a liver-
expressed gene with a well-established role in human disease
(Saraiva 1995). Control animals received LNP-formulated lu-
ciferase siRNA. As shown in Figure 2A, treatment with LNP-
formulated Ttr siRNA resulted in 96 ± 1% (mean ± SD) inhi-
bition of liver TtrmRNA, normalized toGapdh, in treated an-
imals 24 h following administration. Regarding mRNA levels
from serum, administration of the LNP-formulated Ttr
siRNA resulted in a 94 ± 2% reduction in circulating Ttr
mRNA (normalized to Serpina1). These results were extended
to a second liver-specific target gene, Tmprss6 (Finberg et al.
2008), which encodes a transmembrane protein whose levels
cannot be measured in blood. Specifically, a single intrave-
nous dose of 0.3 mg/kg LNP-formulated siRNA targeting
Tmprss6 resulted in reductions of 90 ± 1.3% in Tmprss6
mRNA in the liver and 95 ± 2.5% in serum 24 h after admin-
istration (Fig. 2B). Thus, siRNA-mediated silencing of liver-
expressed genes results in a concomitant reduction in circu-
lating mRNA levels that can be readily detected by analyzing
total RNA obtained by high-speed centrifugation of serum.
These coordinated tissue- and target-specific mRNA reduc-
tions validate the method of circulating extracellular mRNA
detection (cERD). In addition to mRNAs, miRNAs have
been detected in circulation (Hunter et al. 2008). To test
the applicability of cERD to monitor the activity of miRNA-
targeting oligonucleotides, rats were treated with an LNP-for-
mulated oligonucleotide directed against the liver-specific
miRNA miR-122 (anti-miR) (Krutzfeldt et al. 2005; Esau
et al. 2006); control animals received a mismatched oligo-
nucleotide (MM). Three days later, miR-122 levels were
measured in total RNA isolated from liver and serum. As
shown inFigure2C, treatmentwith themiR122-specific oligo-
nucleotide reduced liver miR-122 levels by 88 ± 5% com-
pared with treatment with MM. In serum, a similar decrease
FIGURE 1. Detection of specific RNAs in serum from multiple species. (A) Relative levels of liver-specific (Ttr, Serpina1, Alb, FVII) and ubiquitous
(Gapdh) mRNAs, measured by qPCR in RNA isolated from filtered, centrifuged rat serum. Values are relative to Gapdh levels. Rat serum was pooled
from three animals for this analysis; error bars, SD in experimental replicates. (B) Similar analysis of human and cynomolgus monkey (Macaca fasci-
cularis) circulating RNA. Data shown are fromone pooled human ormonkey sample; error bars, SD among experimental replicates. (C) Two rat serum
samples (S1, 3mL; S2, 3.5mL) were processed for circulating RNA isolation with or without LiCl addition. Relative levels of four differentmRNAswere
measured by qPCR (normalized toGapdh level in the “no LiCl” sample S1). (D) RelativemRNA levels of liver-specific genes TTR and albumin (Alb) as
well as tumor-specific genes AFP and GPC3 as measured by qPCR in RNA isolated from a 75-yr-old male patient with metastatic liver cancer.
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(86 ± 9%) was measured, thus establishing the use of cERD
to monitor miRNA inhibition.
A TTR silencing study was conducted in the cynomolgus
monkey (M. fascicularis) to extend these results to higher spe-
cies. Animals were administered LNP-formulated, TTR-spe-
cific siRNA by intravenous infusion at doses of 0.3, 1, and 3
mg/kg; control animals received LNP-formulated luciferase
siRNA (3 mg/kg). Forty-eight hours after LNP-siRNA ad-
ministration, blood was drawn, and then liver samples were
obtained for analysis. As shown in Figure 2D, liver TTR
mRNA levels were decreased by 34 ± 18% (P < 0.005), 47 ±
15% (P < 0.005), and 59 ± 4% (P < 0.05) following treatment
with 0.3, 1, and 3 mg/kg TTR siRNA, respectively. As moni-
tored by cERD, circulating TTRmRNA levels (normalized to
SERPINA1) were reduced by 40 ± 6% (not significant) and
70 ± 8% (P < 0.005) in the 1 mg/kg and 3mg/kg dose groups,
respectively, but were unchanged in the 0.3 mg/kg dose
group. Taken together with the rat studies, these data estab-
lish the applicability of the cERD method in higher species
and thus the general utility of measuring circulating serum
mRNA to confirm liver gene silencing induced by adminis-
tered siRNA.
Circulating RNA has also been detected in CSF (Harring-
ton et al. 2009). To determine whether cERD could be applied
to CSF to monitor gene silencing in the brain, we infused
siRNA targeting a Parkinson’s disease–associated gene, Snca
(Spillantini et al. 1997), bilaterally into the striatum of rats.
At the end of the 7-d infusion period, brains and CSF were
collected for analysis. Consistent with previous studies dem-
onstrating gene silencing in neuronal cells by intraparenchy-
mal CNS siRNA infusion (Lewis et al. 2008; Querbes et al.
2009), a 33 ± 13% reduction in striatal SncamRNAwas mea-
sured in animals receiving the Snca siRNA compared with
naïve animals. To analyze CSF RNA, pooled samples were
subjected to high-speed centrifugation, and total RNA was
isolated from the pellets. A 61 ± 17% reduction in Snca
mRNA was measured in CSF from Snca siRNA-treated ani-
mals versus controls (Fig. 2E). The greater relative degree of
SncamRNA reduction in theCSF comparedwith the striatum
could be due to variability in the release of RNA by different
FIGURE 2. Silencing of liver mRNA is reflected in circulating mRNA levels. (A) Silencing of rat liver and serum Ttr 48 h after intravenous admin-
istration of 0.3 mg/kg LNP-formulated Ttr siRNA (si-TTR) or Luc siRNA (si-Luc). Levels of Ttrwere normalized toGapdh (liver) or Serpina1 (serum)
levels. Group averages, relative to the si-Luc group, are shown (n = 6 per group). (B) Silencing of rat liver and serum Tmprss6 48 h after intravenous
administration of 0.3 mg/kg LNP-formulated Tmprss6 siRNA (si-TMPRSS6) or Luc siRNA (si-Luc). Levels of Tmprss6 were normalized to Gapdh
(liver) or Serpina1 (serum) levels. Group averages, relative to the si-Luc group, are shown (n = 6 per group). (C) Relative levels of miR-122 detected
by qPCR in equal amounts of total RNA isolated from rat liver or from filtered, centrifuged rat serum obtained 3 d following intravenous adminis-
tration of 1 mg/kg LNP-formulated oligonucleotide targeting miR-122 (anti-miR). Group averages compared to a control group receiving 1 mg/kg
LNP-formulated mismatch control oligonucleotide (MM) are shown (n = 5 per group). Significance was determined by Student’s t-test (∗P < 0.05).
(D) Dose-dependent silencing of cynomolgus monkey (M. fascicularis) liver and serum TTR 48 h after intravenous administration of indicated doses
(mg/kg) of LNP-formulated TTR siRNA (si-TTR). Levels of TTR were normalized to GAPDH (liver) or SERPINA1 (serum) levels. Group averages,
relative to a 3 mg/kg LNP-Luc siRNA-treated control group (si-Luc), are shown (n = 3 per group). Significance relative to the Luc siRNA treated con-
trols was determined by ANOVA (#P < 0.005, †P < 0.05). (E) Relative levels of Snca measured by qPCR in total RNA isolated from the striatum, or
from centrifuged cerebrospinal fluid (CSF) of rats following intraparenchymal CNS infusion of Snca siRNA (siSNCA; n = 27). Snca levels were nor-
malized to Gapdh. Group averages relative to naïve animals (n = 4) are shown. Significance was determined by Student’s t-test (∗P < 0.001, #P < 0.05).
Error bars, SDs for each group.
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regions or cell types of the brain. Regardless, these results con-
firm the suitability of cERD to monitor silencing of a brain-
expressed gene by assaying CSF RNA.
Previous studies have established that administration of
a single dose of LNP-formulated siRNA leads to rapid and
durable target gene silencing in the livers of rodents and
primates (Frank-Kamenetsky et al. 2008; Akinc et al. 2010;
Love et al. 2010). To compare the kinetics of siRNA treat-
ment on levels of circulating and liver mRNA, rats were given
a single dose of 0.1 mg/kg LNP-formulated Ttr siRNA, and
serum and livers were collected 1, 2, 5, 8, 10, and 14 d later;
control animals received LNP-luciferase siRNA. As shown in
Figure 3A, maximal inhibition of TtrmRNA in the liver (95 ±
2%, normalized to Gapdh) and in serum (92 ± 8%, normal-
ized to Serpina1) as monitored by cERD was observed 1 d
following administration of LNP-siRNA targeting Ttr. This
effect was maintained 2 d post-treatment and returned to
near control levels (as assessed by LNP-siRNA targeting lu-
ciferase) by day 10. In a second study, reductions in liver
and serum Ttr mRNA were measured at earlier time points
following siRNA administration. Within 3 h of treatment,
both liver and serum Ttr mRNA levels were reduced by
40%–50%, with peak target reductions of ∼90% achieved
in liver and serum by 12 h (Fig. 3B). Thus, there is a remark-
able concordance of the relative Ttr mRNA levels in the liver
and in serum as measured over time following treatment
with LNP-siRNA, with respect to both onset and duration
of target gene silencing. These results support the conclusion
that monitoring circulating mRNA levels of a liver gene by
cERD provides an accurate representation of tissue-specific
target gene silencing.
A modified RACE-PCR technique has been used to con-
firm the RNA interference mechanism by identification of
the predicted siRNA cleavage product in a number of preclin-
ical and clinical studies (Zimmermann et al. 2006; Frank-
Kamenetsky et al. 2008; Querbes et al. 2009; Davis et al.
2010), including detection of circulating siRNA cleavage in
a recent clinical trial (Coelho et al. 2013). To investigate
whether RNAi in the liver could be demonstrated in circulat-
ing RNA, serum was collected from rats 24 h after treatment
with LNP-formulated Ttr siRNA (or luciferase siRNA con-
trol) and processed as described above to obtain circulating
RNA. Products generated by the modified RACE-PCR meth-
od were cloned, and individual colonies were selected for
sequencing. Out of 45 clones derived from the luciferase
siRNA-treated animals, none corresponded to the predicted
Ttr siRNA cleavage site. In contrast, 15 of 51 clones obtained
from the Ttr siRNA treatment group were found to terminate
precisely at the predicted siRNA cleavage position (P = 0.002)
(for representative sequence traces, see Supplemental Fig.
S1A,B). Similar results were obtained with serum from cyno-
molgus monkeys treated with LNP-formulated TTR siRNA
(Supplemental Fig. S1C). Therefore, the RNA interference
mechanism occurring in liver was molecularly verified by
analysis of circulating RNA in serum.
To extend the analysis beyond endogenously expressed
genes, rats were injected with an adenoviral vector to induce
GFP expression at various levels in the liver (Herrmann et al.
2004). The relative levels of GFPmRNAmeasured in circula-
tion were in good agreement with the corresponding liver
mRNA levels for four animals analyzed 5 d after adenoviral
injection (Fig. 4A). Thus, measurement of mRNA levels in
serum can be applied to the analysis of gene therapy delivery
of exogenous genes.
Wehave shown that analysis of RNA in biological fluids can
be used to quantify the effects of RNA antagonists, such as
siRNA- or miRNA-targeted oligonucleotides, and gene-ex-
pression vectors, such as adenoviral constructs, on RNA levels
in rodent and nonhuman primate tissues. Circulating RNA
was found to correspond closely with tissue RNA levels and
FIGURE 3. Concordance of silencing in liver and circulating RNA. (A) Time course of rat liver and serum Ttr silencing following intravenous ad-
ministration of 0.1 mg/kg LNP-formulated Ttr siRNA (si-TTR). Levels of Ttr were normalized to Gapdh (liver) or Serpina1 (serum) levels. Group
averages, relative to a 0.1 mg/kg LNP-Luc siRNA-treated control group (si-Luc), are shown (n = 7 per group, for each time point). (B) Levels of
rat Ttr mRNA measured by qPCR at the indicated times following intravenous administration of 0.3 mg/kg LNP-formulated Ttr siRNA (si-TTR).
Ttr levels were normalized to levels of Gapdh (liver) or Serpina1 (serum), and group averages were expressed relative to control animals receiving
0.3 mg/kg si-Luc analyzed at 6 h (n = 5 per group). Significance relative to the Luc siRNA-treated control group was determined by ANOVA (∗P
< 0.001; #P < 0.01). Error bars, SDs for each group.
Sehgal et al.
146 RNA, Vol. 20, No. 2
 Cold Spring Harbor Laboratory Press on April 3, 2014 - Published by rnajournal.cshlp.orgDownloaded from 
their modulation by antagonists, suggesting that RNA levels
from biological fluids provide an accurate “real-time” repre-
sentation of tissue RNA status. Importantly, the RNAs de-
tectable in serum correspond to genes that are very highly
expressed (Alb, TTR/Ttr, SERPINA1/Serpina1) as well as
moderately expressed (Tmprss6, F7) in the liver (http://www
.ncbi.nlm.nih.gov/UniGene). Moreover, we were able to de-
tect several other tissue-specific transcripts in circulating
RNA isolated from rat serum (Fig. 4B). We envision that
this cERD method will have broad applicability in clinical
studies since it allows the routine, accurate, and frequentmea-
surement of organ-specific target gene modulation without
the need for tissue biopsies.
MATERIALS AND METHODS
siRNAs, oligonucleotides, and formulations
The LNP formulations used in the rat and cynomolgus monkey
studies were prepared using methods and chemical compositions
similar to those previously described (Zim-
mermann et al. 2006; Akinc et al. 2010).
Chemically modified siRNAs were synthe-
sized at Alnylam (2′-O-methyl-modified nu-





dTsdT; rat Snca, sense AcAccuAAGuGAcuA
ccAcdTsdT and antisense GUGGuAGUcA
CUuAGGUGUdTsdT; cynomolgus monkey
TTR, sense GGAuuucAuGuAAccAAGA and
antisense GUGGuAGUcACUuAGGUGUdTs
dT; and luciferase, sense cuuAcGcuGAGuA
cuucGAdTsdT and antisense UCUUGGUuA
cAUGAAAUCCdTdT. The oligonucleotide
directed against miR-122 and the mismatch
control oligonucleotide were provided by
Regulus Therapeutics, Inc. The sequences
have been described (Krutzfeldt et al. 2005).
Animal experiments
All studies were conducted in accordance with
animal welfare regulations under IACUC-ap-
proved research protocols.
Male Sprague-Dawley rats were adminis-
tered LNP-formulated siRNA or LNP-formu-
lated oligonucleotide as a single injection
via the tail vein at a dose volume of 3 mL/kg
body weight. For the adenovirus studies,
rats received tail vein injections of 1 × 1011
pfu Adeno-GFP (Viraquest) in a volume of
2 mL. Animals were killed at various time
points. To prepare serum, blood was collected
via caudal vena cava into serum separation
tubes and allowed to clot at room temperature
for ∼30 min prior to centrifugation at 4°C. Livers were collected,
frozen in liquid nitrogen, and stored at −80°C.
For brain infusion studies, male Sprague-Dawley rats were anes-
thetized and placed into a stereotaxic frame (Benchmark Digital
Stereotaxic, myNeuroLab). A 30-gauge osmotic pump infusion can-
nula (Plastics One) was implanted into each hemisphere, targeting
the striatum (stereotaxic coordinates AP 0.5, ML 3, and DV 5.1 rel-
ative to bregma; incisor bar 3.3 mm below the interaural line).
Osmotic pumps (1 µL/hr flow rate, Alzet) containing 4 mg/mL
siRNA dissolved in PBS were primed in 0.9% saline overnight at
37°C according to the manufacturer’s instructions, and then con-
nected to the cannula and implanted subcutaneously. After 7 d of
infusion, rats were anesthetized and mounted in a stereotaxic frame.
CSF was collected using a syringe with a 30-gauge needle through
the atlanto-occipital membrane. After CSF collection, rats were
killed, and brains were removed. Coronal slices, 1 mm thick,
through the rat brain from anterior to posterior were obtained using
a brain matrix (Braintree Scientific), and striatum was dissected
from each slice, snap-frozen in liquid nitrogen, and stored at−80°C.
The nonhuman primate study was conducted at Covance Labora-
tories (Madison, WI). Male cynomolgus monkeys (M. fascicularis)
received 15-min infusions of LNP-formulated siRNA via the
FIGURE 4. Extending circulating RNA measurements beyond liver gene silencing. (A) Relative
levels of GFP mRNA measured in total RNA isolated from liver and filtered centrifuged serum
of four individual rats 4 d following intravenous injectionof 1011 pfuAdeno-GFP.Values presented
are themeans of two technical replicates for serum and two technical replicates each from two sep-
arate pieces of liver from each animal. (B) Relative levels of tissue-specificmRNAs (smoothmuscle
actin [Acta2], albumin [Alb], aldolase A [AldoA], apolipoprotein B [ApoB], apolipoprotein E
[ApoE], Gpx2, hepcidin [Hamp], Ptprc, SerpinA1, Tek, TMPRSS6, transthyretrin [TTR], uro-
modulin [UMOD]) measured by qPCR in RNA isolated from rat serum (normalized to GAPDH).
The tissue of origin, as verified from NCBI and http://biogps.org, is marked above each bar.
Circulating RNA quantification of gene modulation
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saphenous vein at a dose volume of 5 mL/kg body weight. Two days
later, animals were anesthetized, and blood was collected from a
femoral vein into serum separator tubes without anticoagulant.
Blood was incubated for 30–60 min at room temperature and cen-
trifuged. Serum was harvested and stored at −80°C. Animals were
killed, and liver samples (∼1 g) were collected, frozen in liquid ni-
trogen, and stored at −80°C.
Serum sample from healthy donors and patients with liver tumors
were obtained from Bioreclamation.
Isolation and analysis of tissue RNA
Total RNA was extracted from frozen rat liver or striatum using the
Qiagen RNeasy kit. For mRNA quantification, cDNA was prepared
with the high-capacity cDNA reverse transcription kit (Applied
Biosystems) using random primers. For miRNA quantification,
cDNA was prepared with the Taqman MicroRNA reverse trans-
cription kit using a miR-122 specific stem–loop primer (Applied
Biosystems). Quantitative PCR was performed on a Roche
LightCycler 480 using Applied Biosystems Taqman gene expression
or miRNA assays (rat Ttr, Rn 01406102; rat Serpina1, Rn 00574670;
rat Tmprss6, Rn01504810; ratAlb, Rn00592480; rat F7, Rn00596104;
rat Snca, Rn01425140; rat Gapdh, 4352338E; miR-122, 002245). A
custom Taqman assay was used to quantify GFP expression (for-
ward, GACAACCACTACCTGAGCAC; reverse, ACCATGTGAT
CGCGCTTC; probe, FAM-CCCTGAGCAAAGACCCCAACGA).
Cynomolgus monkey TTR and GAPDH liver mRNA levels were
measured in Proteinase K–digested liver lysates using gene-specific
branched DNA assays (Panomics).
Isolation and analysis of RNA from serum and CSF
Human serum was obtained from volunteer donors under an IRB-
approved protocol. Rats were killed, and blood was collected from
the vena cava for serum isolation 2.5–3.5 mL serum per rat was
used for each sample. Rat CSF was collected from multiple rats
and pooled for a total volumeof 2mL. Serum (rat, cynomolgusmon-
key, and human) and CSF (rat) were either filtered (0.4 μm) or cen-
trifuged at 10,000g for 10 min prior to mixing with LiCl (final
concentration 1 M diluted from 8 M stock; Ambion) and incubated
for 1 h at 4°C. Tubes were balanced with 1× PBS before spinning at
110,000g for 100–120min. Samples were spun in thick-wall polycar-
bonate tubes inMLA-55 orMLA-130 rotor in BeckmanCoulter cen-
trifuge. The combination of differential centrifugation to collect
RNA in circulating vesicles and of LiCl addition to precipitate free
circulating RNA was intended to maximize total RNA yield. Total
RNA was isolated from pellets by Trizol extraction (Invitrogen)
and isopropanol precipitation. Bioanalyzer (Agilent) analysis of se-
lected RNA samples failed to detect a discrete rRNAband, thus yield-
ing unreliable quantitation results. Synthesis of cDNA and Taqman
gene expression analysis were performed as described above. Human
Taqman gene expression assays: TTR, Hs00174914; SERPINA1,
Hs01097800; TMPRSS6, Hs00542184; ALB, Hs00910225; AFP,
Hs00173490_m1, GPC3,Hs01018938_m1GAPDH, 4326317E. Cus-
tom Taqman assays were used to quantify gene expression in cyno-
molgus monkey serum (TTR: forward, TGGCATCTCCCCATT
CCA, reverse, CGGAATCGTTGGCTGTGAA, probe, FAM-AGCA
TGCAGAGGTGG; SERPINA1: forward, ACTAAGGTCTTCAGC
AATGGG, reverse, GCTTCAGTCCCTTTCTCATCG, probe, FAM-
TGGTCAGCACAGCCTTATGCACG; GAPDH: forward, ATGTT
CCAGTATGATTCCACCC, reverse, CATCGCCCCACTTGATTTT
G, probe, FAM-AGCTTCCCGTTCTCAGCCTTCAC). For the
rat, the assays were the same as described above for tissues and
in addition Acta2, Rn01759928_g1; AldoA, Rn00820577_g1; ApoB,
Rn01499054_m1; ApoE, Rn00593680_m1; Gpx2, Rn00822100_gH;
Hamp, Rn00584987_m1; Ptprc, Rn00709901_m1; Tek, Rn014
33337_m1; and UMOD, Rn00567180_m1.
Ligation-mediated RACE PCR to detect the Ttr siRNA-mediated
cleavage product in rat serum was performed using the GeneRacer
kit (Invitrogen). Nested PCR products were cloned, and individual
clones were sequenced.
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